CTI
  • Italiano Investitori
  • Share
  • About Us
    • Vision & Values
    • Leadership
    • History
    • Collaborations
    • In the Community
    • Careers
    • Media Gallery
    • Contact CTI
  • Products
    • PIXUVRI®
  • Development
    • Pipeline
    • Pacritinib
    • Pixantrone
    • Tosedostat
    • Paclitaxel Poliglumex
    • Publications
  • Clinical Trials
    • Clinical Trial Overview
    • Physician Resources
    • Patient Resources
  • Investors
    • Overview
    • News
    • Stock
      • Stock Chart
      • Historical Price Lookup
      • Investment Calculator
      • Transfer Agent
    • SEC Filings
    • Analyst Coverage
    • Events & Webcasts
    • Annual Report
    • Shareholder Meeting
    • Financial Details
      • Trading Statistics
      • Balance Sheet
      • Income Statement
      • Cash Flow
      • Ratios
    • Corporate Governance
      • Committee Composition
      • Leadership Bios
      • Board of Directors
      • Governance Documents
      • Whistleblower Hotline
    • Investor FAQ
    • Information Request
    • Email Alerts

Investors

  • Overview
  • News
  • Stock
    • Stock Chart
    • Historical Price Lookup
    • Investment Calculator
    • Transfer Agent
  • SEC Filings
  • Analyst Coverage
  • Events & Webcasts
  • Annual Report
  • Shareholders Meeting
  • Financial Details
    • Trading Statistics
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Ratios
  • Corporate Governance
    • Leadership Bios
    • Board of Directors
    • Whistleblower Hotline
  • Investor FAQ
  • Information Request
  • Email Alerts

Info Tools

  • Print Page
  • Email Page
  • RSS Feed
  • Email Alerts
  • IR Contacts
  • Tear Sheet

Most Viewed Links

  • SEC Filings
  • Annual Report
  • Events & Webcasts
  • Stock Quote
  • CTI BioPharma Announces Publication of Pacritinib Phase 3 PERSIST-2 Clinical Trial in JAMA Oncology

Annual Report

If you would like to receive a printed copy of the current annual report, please call
800.215.2355 or 206.272.4345, or complete our Information Request form.

2017 Annual Report (1.30MB PDF)

2016 Annual Report (1.73MB PDF)

2015 Annual Report (3.25MB PDF)

2014 Annual Report (1.36MB PDF)

2013 Annual Report (2.29MB PDF)

2012 Annual Report (5mb)
2011 Annual Report (885kb)

About CTI

  • Vision & Values
  • Leadership
  • History
  • Collaborations
  • In the Community
  • Careers
  • Media Kit
  • Contact CTI
  • Request Information

Products

  • PIXUVRI®

Development

  • Pipeline
  • Pacritinib
  • Pixantrone
  • Tosedostat
  • Paclitaxel Poliglumex
  • Publications

Clinical Trials

  • Clinical Trials Overview
  • Physician Resources
  • Patient Resources
  • Adverse Event Information

Investors

  • Investors Overview
  • News
  • Stock
  • SEC Filings
  • Analyst Coverage
  • Events & Webcasts
  • Annual Report
  • Financial Details
  • Corporate Governance
  • Investor FAQ

Conquering cancer. That's in our blood.

  • Follow us!
  • © 2018 CTI BioPharma Corp. CTI BioPharma and "Conquering cancer. That’s in our blood." are trademarks of CTI BioPharma Corp.
  • Terms of Use
  • Privacy Policy